SPDR S&P Biotech ETF
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
25% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 73
17% more funds holding in top 10
Funds holding in top 10: 18 [Q2] → 21 (+3) [Q3]
1% more funds holding
Funds holding: 749 [Q2] → 758 (+9) [Q3]
4% more capital invested
Capital invested by funds: $10.9B [Q2] → $11.4B (+$473M) [Q3]
9.24% less ownership
Funds ownership: 154.53% [Q2] → 145.29% (-9.24%) [Q3]
13% less repeat investments, than reductions
Existing positions increased: 234 | Existing positions reduced: 269
16% less call options, than puts
Call options by funds: $2.8B | Put options by funds: $3.33B
Research analyst outlook
We haven’t received any recent analyst ratings for XBI.
Financial journalist opinion
Based on 7 articles about XBI published over the past 30 days
Positive
Seeking Alpha
1 week ago
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.
Positive
Seeking Alpha
1 week ago
3 Oversold Biotech Names
High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens today and runs through most of the week could boost sentiment on the biotech sector. In the paragraphs below, I highlight three biotech/biopharma names that appear oversold at current trading levels.
Neutral
CNBC Television
2 weeks ago
Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared Holz
Jared Holz, Mizuho Securities America healthcare sector strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on the healthcare sector in the new year
Positive
Seeking Alpha
2 weeks ago
Healthcare Stocks: 2025 Outlook
I forecast healthcare stocks, especially biopharmaceuticals, to outperform the general averages due to four key investment themes. US healthcare expenditures are expected to grow at an annualized rate of 6% through 2030, reaching $7.3 trillion.
Positive
CNBC Television
2 weeks ago
Trade Tracker: Joe Terranova buys the XBI
Joe Terranova, senior managing director for Virtus Investment Partners, joins CNBC's 'Halftime Report' to discuss why he's buying the Biotech ETF.
Neutral
Zacks Investment Research
2 weeks ago
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Making its debut on 01/31/2006, smart beta exchange traded fund SPDR S&P Biotech ETF (XBI) provides investors broad exposure to the Health Care ETFs category of the market.
Neutral
CNBC Television
4 weeks ago
Final Trade: LNG, XLP, X, XBI
The final trades of the day with CNBC's Dominic Chu and the Fast Money traders.
Positive
Market Watch
1 month ago
RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead
Stem-cell research is on the cusp of a breakthrough that could come as soon as 2025, and two biotech companies with promising therapies stand to gain, according to a new report from Maxim Group on Thursday.
Neutral
Zacks Investment Research
1 month ago
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund launched on 01/31/2006.
Neutral
Seeking Alpha
1 month ago
Finding Winners In Biotech, Probably The Riskiest Sector
Investing in biotech offers high upside but comes with significant risks, especially with volatile stock movements and binary outcomes from clinical trials, says Jonathan Faison. Focus on multi-year clinical and commercial momentum, diversifying with multiple drug candidates.
Charts implemented using Lightweight Charts™